Company roundup

  • Updated: June 21, 2013 - 8:03 PM

DEBT AND EQUITIES

BioSante Pharmaceuticals, Baudette, received a letter from Nasdaq informing BioSante that, since the merger with ANIP Acquisition Co. earlier this week, BioSante was required to meet the initial listing criteria for the Nasdaq Global Market. BioSante did not meet the minimum $4 bid price requirement for initial listings and Nasdaq decided to delist BioSante’s securities. BioSante intends to appeal the decision.

  • get related content delivered to your inbox

  • manage my email subscriptions

ADVERTISEMENT

Connect with twitterConnect with facebookConnect with Google+Connect with PinterestConnect with PinterestConnect with RssfeedConnect with email newsletters

ADVERTISEMENT

Advertisement
Golden Gavel by Star Tribune

Time left for great deals

Bid thru Sept. 29

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

 
Close